Quick Answer
Axsome Therapeutics, Inc. reported Research And Development Expense of $183.28 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed a decrease of -2.0% in Research And Development Expense from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Axsome Therapeutics, Inc.'s Research And Development Expense has grown by 4,183.0%.
- Historical annual values: Fiscal year 2025: $183.28 million | Fiscal year 2024: $187.08 million | Fiscal year 2023: $97.94 million | Fiscal year 2022: $57.95 million | Fiscal year 2021: $58.06 million | Fiscal year 2020: $70.24 million | Fiscal year 2019: $53.65 million | Fiscal year 2018: $23.50 million | Fiscal year 2017: $19.96 million | Fiscal year 2016: $21.20 million | Fiscal year 2015: $6.78 million | Fiscal year 2014: $4.28 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: